FibroGen’s $120 Million Shelf Takedown

Cooley advised FibroGen on its $120 million shelf takedown of 5,228,750 shares of common stock.

FibroGen, which is headquartered in San Francisco and trades on The NASDAQ Global Select Market as “FGEN,” is a research-based biopharmaceutical company using its expertise in connective tissue growth factor and hypoxia-inducible factor biology to discover, develop and commercialize novel therapeutics for serious unmet medical needs.

Cooley has advised with a team including Glen Sato (Picture), Michael Tenta, Clark Chu, Erin Kravitz, Donna Salcedo, Allison Pang, Natasha Leskovsek and Francis Wheeler.

Involved fees earner: Glen Sato – Cooley LLP; Michael Tenta – Cooley LLP; Clark Chu – Cooley LLP; Erin Kravitz – Cooley LLP; Donna Salcedo – Cooley LLP; Allison Pang – Cooley LLP; Francis Wheeler – Cooley LLP;

Law Firms: Cooley LLP;

Clients: FibroGen, Inc.;

Print Friendly, PDF & Email

Author: Ambrogio Visconti